Abstract: An electrode, comprising: a portion of MXene, the portion of MXene optionally being free of materials other than the MXene; and (a) a sealing material, the sealing material at least partially enclosing the portion of MXene, and the sealing material defining an opening through which a sensing region of the portion of MXene is exposed; or (b) a substrate, the portion of MXene being disposed on the substrate. An electrode, comprising: a fiber; a first coating superposed on the fiber, the first coating having a thickness and comprising a MXene composition, the MXene composition optionally comprising aligned MXene flakes, the first coating optionally having a uniform thickness along the length of the fiber; and a second coating superposed on the fiber.

Abstract: The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein V; W; X; Y; Z; R1; R2; R3; R4 and R5 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

Abstract: A respiratory system includes a first patient interface for delivery of a flow of gases to a patient, a second patient interface for delivery of a second flow of gases to the patient, and a device that switches the system between a first respiratory mode and a second respiratory mode. In the first respiratory mode, the flow of gases are delivered to an outlet of the first patient interface when the second patient interface is absent from the patient. In the second respiratory mode the device reduces or stops delivery of the first flow of gases to the outlet of the first patient interface when the second patient interface is located together with the first patient interface upon the patient.

Abstract: Several methods of supporting respiratory function of a patient before, during and/or after a medical procedure are disclosed. In certain arrangements, supporting respiratory function while a patient is under general anaesthesia can include providing a high gas flow a high gas flow that is greater than 15 L/min while the patient is under general anaesthesia.

Abstract: A method for providing respiratory support to a patient includes intubating the patient with an invasive patient interface having a sealable member operable to form a sealing engagement with the patient's airway. While the patient is intubated, the sealable member is operated to form a non-sealing arrangement of the invasive patient interface within the patient's airway and a flow of respiratory gas is provided to the patient via the invasive patient interface. This respiratory support is provided during absence of spontaneous breathing.

Abstract: The invention relates to a respiratory system comprising a first patient interface for delivery of a first flow of gases to a patient, a second patient interface for delivery of a second flow of gases to the patient, and a device and/or sensing arrangement that is configure to facilitate a switching of the system between a first respiratory mode where the device allowing delivery of the first flow of gases to an outlet of the first patient interface when the second patient interface is absent from the patient, and a second respiratory mode where the device reducing or stopping delivery of the first flow of gases to the outlet of the first patient interface when the second patient interface is located together with the first patient interface upon the patient.

Abstract: Several methods of supporting respiratory function of a patient before, during and/or after a medical procedure are disclosed. In certain arrangements, supporting respiratory function while a patient is under general anaesthesia can include providing a high gas flow a high gas flow that is greater than 15 L/min while the patient is under general anaesthesia. In certain arrangements, a method of providing ventilation while a patient is under general anaesthesia involves providing only a gas flow delivered through a nasal interface that is greater than 15 L/min while the patient is under general anaesthesia.

Abstract: The invention relates to a respiratory system comprising a first patient interface for delivery of a first flow of gases to a patient, a second patient interface for delivery of a second flow of gases to the patient, and a device and/or sensing arrangement that is configure to facilitate a switching of the system between a first respiratory mode where the device allowing delivery of the first flow of gases to an outlet of the first patient interface when the second patient interface is absent from the patient, and a second respiratory mode where the device reducing or stopping delivery of the first flow of gases to the outlet of the first patient interface when the second patient interface is located together with the first patient interface upon the patient.

Abstract: Several methods of supporting respiratory function of a patient before, during and/or after a medical procedure are disclosed. In certain arrangements, supporting respiratory function while a patient is under general anaesthesia can include providing a high gas flow a high gas flow that is greater than 15 L/min while the patient is under general anaesthesia.

Abstract: A method of determining a duration of safe apnoea. Information is obtained relating to a respiratory indicator, which can include information relating to a potential respiratory equilibrium, and a duration of safe apnoea is determined from the obtained information.

Abstract: Several methods of supporting respiratory function of a patient before, during and/or after a medical procedure are disclosed. In certain arrangements, supporting respiratory function while a patient is under general anaesthesia can include providing a high gas flow that is greater than 15 L/min while the patient is under general anaesthesia. In certain arrangements, a method of providing ventilation while a patient is under general anaesthesia involves providing only a gas flow delivered through a nasal interface that is greater than 15 L/min while the patient is under general anaesthesia.

Abstract: The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein V; W; X; Y; Z; R1; R2; R3; R4 and R5 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

Abstract: The disclosures herein relate to novel compounds of formula (I): and salts thereof, wherein W; X; Y; Z; R1; R2; R3 and R4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

Abstract: Systems, methods, and devices for neuromodulation are described herein. For example, a method for modulating inflammatory processes of a subject is described. The method can include stimulating the subject's vagus nerve to activate an efferent pathway, and stimulating the subject's vagus nerve to inhibit neural activity. Pairing activation of the efferent pathway and inhibition of neural activity can enhance an anti-inflammatory response of the subject.

Abstract: The invention relates to a respiratory system comprising a first patient interface for delivery of a first flow of gases to a patient, a second patient interface for delivery of a second flow of gases to the patient, and a device and/or sensing arrangement that is configure to facilitate a switching of the system between a first respiratory mode where the device allowing delivery of the first flow of gases to an outlet of the first patient interface when the second patient interface is absent from the patient, and a second respiratory mode where the device reducing or stopping delivery of the first flow of gases to the outlet of the first patient interface when the second patient interface is located together with the first patient interface upon the patient.

Abstract: This invention relates to a respiratory therapy system comprising a first patient interface for delivery of a flow of gas to a patient, and a second patient interface for delivery of a flow of gas to the patient, or devices or interfaces for use in such systems.

Abstract: The invention relates to a respiratory system comprising a first patient interface for delivery of a first flow of gases to a patient, a second patient interface for delivery of a second flow of gases to the patient, and a device and/or sensing arrangement that is configure to facilitate a switching of the system between a first respiratory mode where the device allowing delivery of the first flow of gases to an outlet of the first patient interface when the second patient interface is absent from the patient, and a second respiratory mode where the device reducing or stopping delivery of the first flow of gases to the outlet of the first patient interface when the second patient interface is located together with the first patient interface upon the patient.

Abstract: A guiding device for use with a laryngoscope for assisting in the insertion of an endotracheal tube into a patient, the device comprising a guiding means for guiding an endotracheal tube through the patient's upper airways, and an attachment means to attach the guiding means to the blade of the laryngoscope. A laryngoscope comprising the guiding device is also disclosed.

Abstract: Systems, methods, and devices for neuromodulation are described herein. For example, a method for modulating inflammatory processes of a subject is described. The method can include stimulating the subject's vagus nerve to activate an efferent pathway, and stimulating the subject's vagus nerve to inhibit neural activity. Pairing activation of the efferent pathway and inhibition of neural activity can enhance an anti-inflammatory response of the subject.

Abstract: A compound which is a benzimidazolyl isoxazole of formula (I): wherein: R0 and R, which are the same or different, are each H or C1-6 alkyl; R9, R9 and R9, which are the same or different, are each H or F; X is -(alkn-, -alk-C(?O)—NR—, -alk-NR—C(?O)— or -alk-C(?O)—; R1 is selected from —S(?O)2R?; a 4- to 6-membered, C-linked heterocyclic group which is unsubstituted or substituted; and an N-linked spiro group of the following formula: R2 and R2?, which are the same or different, are each H or C1-6 alkyl, or R2 and R2? form, together with the C atom to which they are attached, a C3-6 cycloalkyl group; R3 and R3, which are the same or different, are each H, C1-6 alkyl, OH or F; R4 is phenyl or a 5- to 12-membered, N-containing heteroaryl group and is unsubstituted or substituted; alk is C1-6 alkylene; R? is C1-6 alkyl; and n is 0 or 1; or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.